Prescribing information

 

JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. JAKAVI® is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids. JAKAVI® is indicated for the treatment of patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids.1

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Polycythaemia vera (PV) is a myeloproliferative disorder that causes overproduction of red blood cells and is characterised by high symptom burden, risk of thrombotic events and disease transformation, and shortened life expectancy.9,10

Take these short modules to learn about the range of symptoms experienced by patients with PV, the diagnostic process, the signs of disease progression and the treatment options available.

This content is intended for UK healthcare professionals only and has been sponsored and funded by Novartis Pharmaceuticals UK Ltd.

 

Overview

Module 1

The symptom burden, complications and prognosis of polycythaemia vera

Module 2

Timely management of polycythaemia vera: considerations and pitfalls

Take these short modules to learn about the range of symptoms experienced by patients with PV, the diagnostic process, the signs of disease progression and the treatment options available.

Module 1

The symptom burden, complications and prognosis of polycythaemia vera

In this module you will gain an increased awareness of the diagnostic criteria for PV as well as the range of symptoms experienced by patients and the risk of disease progression.

Start module 1

Module 2

Timely management of polycythaemia vera: considerations and pitfalls

Complete this module to learn more about the different treatment options available for PV and their limitations, and understand the risks associated with insufficient control of PV.

Start module 2

References

  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
  2. Scottish Medicines Consortium. Ruxolitinib (Jakavi®). Available at: https://www.scottishmedicines.org.uk/medicines-advice/ruxolitinib-jakavi... [Accessed November 2023].
  3. Vannucchi AM, et al. N Engl J Med 2015;372:426–435.
  4. Verstovsek S, et al. Haematologica 2016;101:821–829.
  5. Griesshammer M, et al. Ann Hematol 2018;97:1591–1600.
  6. Griesshammer M, et al. Ann Hematol 2018;97:1591–1600. Supplementary appendix.
  7. Verstovsek S, et al. N Engl J Med 2012;366:799–807.
  8. Harrison C, et al. N Engl J Med 2012;366:787–798
  9. Teeri A, et al. Leukemia 2021;35(12):3339–3351.
  10. Harrison CN, et al. Ann Hematol 2017;96(10):1653–1665.
Rate this content: 
Average: 4 (1 vote)
UK | November 2023 | 318437

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]